Previous Close | 69.42 |
Open | 69.89 |
Bid | 70.34 x 1200 |
Ask | 70.41 x 900 |
Day's Range | 69.28 - 70.76 |
52 Week Range | 51.79 - 89.91 |
Volume | |
Avg. Volume | 1,097,288 |
Market Cap | 11.065B |
Beta (5Y Monthly) | 1.22 |
PE Ratio (TTM) | 50.64 |
EPS (TTM) | 1.39 |
Earnings Date | May 01, 2024 - May 06, 2024 |
Forward Dividend & Yield | 0.32 (0.45%) |
Ex-Dividend Date | Feb 09, 2024 |
1y Target Est | 80.42 |
Subscribe to Yahoo Finance Plus to view Fair Value for TECH
Bio-Techne Corporation (NASDAQ: TECH) is pleased to announce that Lunaphore, part of Bio-Techne's Spatial Biology Division, is partnering with Nikon Instruments Inc. (Nikon) to expand access to spatial biology services with the COMET™ platform for US-based biotech, pharma, and academic customers.
Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, part of Bio-Techne's Molecular Diagnostics Division, has completed the Class C Certification under the new European Union In Vitro Diagnostic Regulation (IVDR) for its QuantideX® qPCR BCR-ABL IS Kit. Previously, the kit was CE-IVD marked for sale in the EU in compliance with the In Vitro Diagnostic Directive (IVDD), which has now been replaced by the IVDR.
Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation. First, the hard data supports bullishness in biotech stocks. According to Grand View Research, the underlying global industry reached a valuation of $1.55 trillion last year. Moving forward, experts project that the sector will expand at a compound annual growth rate (CAGR) of 13.96% from 2024 to 2030. At the culmination point, the space may be worth $3.88 trillion. Second, a sector r